News and Announcements
Imugene Ltd (ASX: IMU) Seeking Capital for HER-Vaxx
- Published November 21, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Imugene Ltd (ASX: IMU) is raising capital for further immuno-oncology clinical testing
- HER-Vaxx, an anti-cancer vaccine therapy, has been utilised in initial clinical testing on patients with gastric cancer.
- The ASX has granted a halt on trade allowing the company to prepare.
Imugene Ltd (ASX: IMU), a clinical-stage immuno-oncology company treating gastric, breast, ovarian, lung & pancreatic cancers, has arranged a halt on trade approved by the Australian Stock Exchange.
This halt comes about as a result of the company’s desire to raise capital. The halt will allow Imguene to have sufficient preparation time.
HER-Vaxx, the leading Imugene product that capitalises on the body’s ability to create antibodies against disease, has commenced clinical testing on gastric cancer patients.
Two leading antibody medications apply the same method as HER-Vaxx employs, utilising the same receptor. These alternative products possessing annual sales of US $8.2 billion.
About Imugene Ltd (ASX: IMU)
Imugene is a clinical stage immuno-oncology company. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
